OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans

Viola Viviani, Adele Fantoni, Sara Tomei, Sara Marchi, Enrico Luzzi, Margherita Bodini, Alessandro Muzzi, Marzia M. Giuliani, Domenico Maione, Jeremy Derrick, Isabel Delany, Mariagrazia Pizza, Alessia Biolchi, Erika Bartolini

Research output: Contribution to journalArticlepeer-review


The ability of Neisseria meningitidis Outer Membrane Vesicles (OMV) to induce protective responses in humans is well established and mainly attributed to Porin A (PorA). However, the contribution of additional protein antigens to protection remains to be elucidated. In this study we dissected the immunogenicity of antigens originating from the OMV component of the 4CMenB vaccine in mice and humans. We collected functional data on a panel of strains for which bactericidal responses to 4CMenB in infants was attributable to the OMV component and evaluated the role of 30 OMV-specific protein antigens in cross-coverage. By using tailor-made protein microarrays, the immunosignature of OMV antigens was determined. Three of these proteins, OpcA, NspA, and PorB, triggered mouse antibodies that were bactericidal against several N. meningitidis strains. Finally, by genetic deletion and/or serum depletion studies, we demonstrated the ability of OpcA and PorB to induce functional immune responses in infant sera after vaccination. In conclusion, while confirming the role of PorA in eliciting protective immunity, we identified two OMV antigens playing a key role in protection of infants vaccinated with the 4CMenB vaccine against different N. meningitidis serogroup B strains.
Original languageEnglish
Article number54
Journaln p j Vaccines
Issue number1
Publication statusPublished - 12 Apr 2023


Dive into the research topics of 'OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans'. Together they form a unique fingerprint.

Cite this